Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 315.94M P/E 19.64 EPS this Y -250.00% Ern Qtrly Grth -
Income 2.51M Forward P/E -32.35 EPS next Y -450.00% 50D Avg Chg -12.00%
Sales 192.64M PEG -2.42 EPS past 5Y -17.19% 200D Avg Chg -26.00%
Dividend N/A Price/Book 0.59 EPS next 5Y 36.10% 52W High Chg -50.00%
Recommedations 3.00 Quick Ratio 4.82 Shares Outstanding 57.54M 52W Low Chg -
Insider Own 5.21% ROA -1.36% Shares Float 52.05M Beta 0.78
Inst Own 89.45% ROE 0.47% Shares Shorted/Prior 2.07M/3M Price 5.50
Gross Margin 92.32% Profit Margin 1.30% Avg. Volume 586,569 Target Price 5.25
Oper. Margin -15.67% Earnings Date May 1 Volume 622,323 Change -2.48%
About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Vanda Pharmaceuticals Inc. News
04/25/24 UPDATE 1-Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer
04/25/24 Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals
04/24/24 Vanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Know
04/24/24 Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
04/22/24 Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
04/22/24 UPDATE 1-U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
04/22/24 U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
04/19/24 Butler Hall Capital urges Vanda to engage in sales discussions
04/18/24 Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up
04/18/24 Investors Heavily Search Vanda Pharmaceuticals Inc. (VNDA): Here is What You Need to Know
04/17/24 Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak's Takeover Bid Valued Up To $7.75/Share
04/17/24 Why Vanda Pharmaceuticals Stock Is Skyrocketing Today
04/17/24 Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
04/17/24 Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
04/15/24 Vanda Pharmaceuticals (VNDA) Declines More Than Market: Some Information for Investors
04/10/24 Vanda Pharmaceuticals (VNDA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
04/08/24 AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors
04/04/24 Vanda (VNDA) Soars 29.2%: Is Further Upside Left in the Stock?
04/03/24 Vanda (VNDA) Up on FDA Nod for Fanapt in Bipolar I Disorder
04/03/24 Here's Why Amgen (AMGN) Stock is Outperforming the Industry
VNDA Chatroom

User Image TheBiotechInvestor_ Posted - 10 hours ago

$VNDA As previously predicted in my video, this is a strong company that really knows how to manage its tools and cash, constantly increasing revenue and profitability. Looking forward to the Ponvoroy sales for Q1. The bid to buyout Vanda came to be as a surprise. I believe that the Gastroparesis PDUFA coming up is solid. Looking forward to hear about the Poison Pill adoption by the CEO and board. New video coming post Earnings. https://youtu.be/K1JIjwA6_Uk?si=usy6Qf_Ap4ABmsBm

User Image Ulong Posted - 15 hours ago

$VNDA ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 https://www.sec.gov/ix?doc=/Archives/edgar/data/0001347178/000121390024036802/ea0204298-01.htm

User Image Ulong Posted - 15 hours ago

$VNDA "Dear Stockholder: You are cordially invited to attend the Annual Meeting of Stockholders (the “Annual Meeting”) of Vanda Pharmaceuticals Inc., a Delaware corporation (the “Company”). The Annual Meeting will be held on May 17, 2024, at 9:00 a.m. Eastern Time in a virtual meeting format only via webcast on the Internet. You will be able to attend and participate in the virtual Annual Meeting online by visiting the meeting website at www.virtualshareholdermeeting.com/VNDA2024 and entering your 16-digit control number included on your proxy card. We are committed to ensuring, to the extent possible, that stockholders will be afforded the ability to participate at the virtual meeting like they would at an in-person meeting. Additional details on how to participate in the Annual Meeting can be found in the Questions and Answers section below. The Annual Meeting is being held for the following purposes: ... Read the SEC filing: https://www.sec.gov/ix?doc=/Archives/edgar/data/0001347178/000121390024036802/ea0204298-01.htm

User Image TrollingST Posted - 17 hours ago

$VNDA Dayum lol 100k bid at 4.75

User Image HappyTrader2022 Posted - 17 hours ago

$VNDA

User Image Rasto2020 Posted - 21 hours ago

$VNDA look at that ,.. good morning everyone. It’s ready

User Image permabear123 Posted - 1 day ago

$VNDA why so much insider selling in march in the $4’s? Especially with $7 offer? Anyone!?

User Image biid Posted - 2 days ago

$VNDA If these are truly the tutes' average prices, there's no way this company is being sold under $10. Hell, there's no way it's being sold under $15, or even $20.

User Image Rasto2020 Posted - 3 days ago

$VNDA clearly uptrend and seems it might repeat the previous pattern. Anyhow, I wish everyone a wonderful weekend and go spend time with your loved ones because money will always be there, but not the loved ones. God bless you all

User Image Unicorn2020 Posted - 3 days ago

$VNDA The CEO, also the Chairman of the board, only owns 3.25% of the company stock. The largest shareholder is Blackrock 14.51%, so he alone can't decide at what price this company will be sold, Blackrock will. We have an FDA decision coming in September. If denied, the BO offer @ $7.50 will stand. If we get the approval, the stock will hit above 12-month high. And all new higher offers will be pouring in. Be patient!

User Image TrollingST Posted - 3 days ago

$VNDA How is this trading below all of these institutional averages? Not a single tute has bought this below $5.34 and 94.42% is owned by them. The other 5.7% is owned by insiders. They're just playing hot potato with the borrowed shares? So the math is 57.54 million owned by Institutions and insiders, 2 million shorted by the market. Something is off here.

User Image BioRich Posted - 3 days ago

$VNDA not sure why the sentiment is bullish on this as they have already had an unsolicited hostile takeover proposal at ~ 65% premium of current share price. I'd like to see a PR from the board of why they rejected. Can't help but think they have bigger plans/offers coming.

User Image biid Posted - 3 days ago

$VNDA Bought some more yesterday and today. Couldn't resist at these prices. Continued sales success of the company will give management leverage regarding BO possibility, which will drive up price. The BO itself may never even happen. And I hope it doesn't. I want my long-term gains! Be patient and HOLD! This company will reward you.

User Image Rounderssss4 Posted - 3 days ago

$VNDA They haven't announced a earnings date yet , TD shows may 1st which is Wednesday, interesting

User Image Rasto2020 Posted - 4 days ago

$VNDA if this repeats same pattern as from beginning of April then next week this will run again.

User Image essiepaul Posted - 4 days ago

$VNDA from over $20 in 2021 to $4.50 in ‘24. Time for mgmt to either make some changes or sell to someone who is serious about some type of value creation for shareholders. Salaries these guys are getting for this awful performance is insane. Amazing some of the large institutions that hold stock are not more active in seeking a combination. Would bet there is another pop coming in SP

User Image Bornjever Posted - 4 days ago

$VNDA sales on newly approved drugs will not show up till next quarter but this cost some of us quite a bit so I hope something comes of it as this is good company but BIO is scary for lots because of heavy shorting and day traders hardly ever leave money in over night and you can see prices drop almost every night. Just got burned by ABEO FDA delayed PDUFA because purity had to be guaranteed by process so my money is tied up till late summer but they said otherwise approved. Still

User Image biid Posted - 4 days ago

$VNDA Screw Future Pak. Screw Shareholder Capital (and their measly 200K shares. The best move management can make for shareholders is to stand firm and deliver its earnings call as scheduled. I hope their results will be spectacular: PONVORY $15 million in sales, FANAPT for Bipolar 1 selling like hotcakes! I'm not selling below $25-30. These bozos' offer of $7.25-7.75 is peanuts and anyone with a brain knows it! I hope and believe this management team is too smart to fall for BS like that. Don't give into the pressure!

User Image Capitulation_0 Posted - 4 days ago

$VNDA This does have around 90% institutional ownership, which to me seems quite high given the underperformance.. Perhaps, they've crowded due to low valuation, trading below cash. If they do a formal sale process, I think they can get north of $10.

User Image Capitulation_0 Posted - 4 days ago

$VNDA pretty angry and (damning? ) letter by both Sharecap and Butler Hall.. Too bad they're just small holders.

User Image Rounderssss4 Posted - 4 days ago

$VNDA Hopefully vnda lets future pak do it's due diligence, and comes back with a stronger offer. And this sale is completed. In the meantime just add

User Image Capitulation_0 Posted - 4 days ago

$VNDA I agree with the letter 100%.. it's been very small funds that are pushing...Bigger fund have been silent. These are mostly non activist funds so I don't expect them to say anything publically. More activist focused funds could come in... or the management could just decided to sell given the pressure and offer out there.

User Image Capitulation_0 Posted - 4 days ago

$VNDA here's the latest funds pushing for a sale: https://ml.globenewswire.com/Resource/Download/9fb456e3-2227-470c-9737-fa3d0566f018

User Image Capitulation_0 Posted - 4 days ago

$VNDA Simplifying a bit but why wouldn't activist come in here to push for a sale?

User Image BioRich Posted - 4 days ago

@Find_the_Cure no problem at all. I don't mind being called out as a pumper if something doesn't look right because I k kw there are many out there that do it to recover losses. I like to post about things I believe in and have researched. With that being said, * * $ADXN has been crushed lately for no reason. Believe they are a big BO target. I am also strong on * $VTGN as they have had success so far in their clinical trials treating Social Anxiety Disorder, which is a huge unmet market that will ring in monstrous revenue if/when approved. *$ARRNF is a rare metals company that's pennies right now but struck big in their Wyoming underground exploration. This helps ensure US isn't as reliant on other nations when it comes to obtaining ever-so valuable rare earth metals. * $VNDA recently rejected a bid from Future Pak offering to buy outstanding shares for around 7.50$/share.

User Image TrollingST Posted - 5 days ago

$VNDA Intereting trade. 274K after hours.

User Image deemancpa Posted - 5 days ago

$VNDA do we have an F'n buyer yet?

User Image Rasto2020 Posted - 5 days ago

$VNDA I am back in with $4.60 average

User Image novoiceinvestor Posted - 5 days ago

$VNDA Has anyone (besides the hedge fund) spoke to the IR or wrote them expressing their displeasure with the handling of the BO offer and implementation of the poison pill? @TwongStocks Are you in this too my friend? Just recently opened a position because of the BO offer. I hope it's not a mistake LOL.

User Image ZonataTwits Posted - 5 days ago

$VNDA trying to see where is the bottom... I'd like to take a small speculative bet.

Analyst Ratings
Jefferies Hold Feb 25, 22
B of A Securities Buy May 12, 21
Citigroup Neutral Jan 14, 21
Citigroup Buy Oct 29, 20
Citigroup Neutral Jun 9, 20
Citigroup Buy Mar 12, 20
Stifel Hold Feb 26, 20
JMP Securities Market Outperform Feb 26, 20
Citigroup Buy Aug 1, 19
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Wijkstrom Joakim SVP, Chief Marketing.. SVP, Chief Marketing Officer Aug 21 Sell 5.84 3,724 21,748 113,816 08/23/23
Polymeropoulos Mihael Hristos President and CEO President and CEO Dec 05 Option 3.12 150,000 468,000 1,455,116 12/07/22
Polymeropoulos Mihael Hristos President and CEO President and CEO Dec 05 Sell 10.62 95,900 1,018,458 1,406,866 12/07/22
Moran Kevin Patrick SVP, CFO & Treasurer SVP, CFO & Treasurer Dec 06 Option 3.12 7,500 23,400 124,952 12/07/22
Moran Kevin Patrick SVP, CFO & Treasurer SVP, CFO & Treasurer Dec 06 Sell 10.61 4,792 50,843 120,160 12/07/22
Birznieks Gunther SVP, Business Develo.. SVP, Business Development Aug 26 Option 3.12 1,250 3,900 190,057 08/29/22
Wijkstrom Joakim SVP, Chief Marketing.. SVP, Chief Marketing Officer Aug 22 Sell 10.2656 3,605 37,007 96,673 08/23/22
Moran Kevin Patrick SVP, CFO & Treasurer SVP, CFO & Treasurer Jul 28 Sell 10.97 2,239 24,562 117,452 08/01/22
Mitchell Stephen Ray Director Director Jun 13 Sell 9.4789 2,700 25,593 6,515 06/14/22
Williams Timothy SVP & General Counse.. SVP & General Counsel Feb 28 Sell 11.09 12,060 133,745 103,851 03/02/22
Wijkstrom Joakim SVP, Chief Marketing.. SVP, Chief Marketing Officer Feb 28 Sell 11.19 6,974 78,039 100,278 03/02/22
Polymeropoulos Mihael Hristos President and CEO President and CEO Feb 28 Sell 11.17 37,096 414,362 1,352,766 03/02/22
Moran Kevin Patrick SVP, CFO & Treasurer SVP, CFO & Treasurer Feb 28 Sell 11.24 12,305 138,308 119,691 03/02/22
Birznieks Gunther SVP, Business Develo.. SVP, Business Development Feb 28 Sell 11.23 15,601 175,199 188,807 03/02/22
Jones Aranthan II Chief Corp. Affairs.. Chief Corp. Affairs Officer Sep 17 Sell 16.49 16,824 277,428 81,980 09/17/21
Jones Aranthan II Chief Corp. Affairs.. Chief Corp. Affairs Officer Sep 17 Option 11.8 12,119 143,004 98,804 09/17/21
Williams Timothy SVP & General Counse.. SVP & General Counsel Mar 03 Sell 18.57 19,530 362,672 92,526 03/03/21
Watkins Thomas Director Director Feb 18 Option 7.11 15,000 106,650 55,323 02/18/21
Watkins Thomas Director Director Feb 18 Sell 18.54 5,818 107,866 49,505 02/18/21
DUGAN RICHARD W Director Director Feb 18 Option 7.11 15,000 106,650 60,641 02/18/21
DUGAN RICHARD W Director Director Feb 18 Sell 18.54 5,754 106,679 54,887 02/18/21